Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer
Season 1, Episode 33, Oct 11, 2021, 01:00 PM
This episode features an examination of an article from the September issue of the journal ONCOLOGY, titled “Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.” CancerNetwork spoke with one of the authors of this research, Jun Gong, MD, a practicing medical oncologist with an emphasis in GU cancers at Cedars-Sinai Medical Center.
Gong detailed PSA’s role in prostate cancer, and other potential complementary biomarkers. He also discussed some of the significant findings from his research on plasma glutamine, which featured a cohort of over 100 patients with localized prostate cancer.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.